2-Allyl-1,3-propane diamine | 135460-65-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Allyl-1,3-propane diamine
• 英文别名: 2-Prop-2-enylpropane-1,3-diamine
• CAS: 135460-65-0
• 化学式: C₆H₁₄N₂
• mdl: MFCD19207307
• 分子量: 114.191
• InChiKey: OPBRDYYWYDROKV-UHFFFAOYSA-N

物化性质

• 沸点：
  194.7±20.0 °C(Predicted)
• 密度：
  0.875±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-Allyl-1,3-propane diamine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 48.0h， 生成 2-(2,3-epoxypropyl)-N,N'-bis(tert-butyloxycarbonyl)-1,3-propanediamine
  参考文献：
  名称：

  The Synthesis and in vitro Evaluation of a 99mTechnetium-Nitroimidazole Complex Based on a Bis(amine-phenol) Ligand: Comparison to BMS-181321

  摘要：

  We have developed a (99m)Technetium complex for imaging of hypoxic tissue (BMS-181321). Recently, another nitroimidazole derivative, based upon a bis(amine-phenol) ligand, was described in the patent literature. To compare this compound to BMS-181321, we have synthesized the ligand, prepared its Tc-99m complex, and evaluated its performance in two in vitro assays of bioefficacy: membrane permeability and uptake in normoxic and anoxic cardiocytes. In attempting to reproduce the synthesis of the ligand described in the patent application, we found that one intermediate could not be made by the method described, and alternative routes were investigated. Complexation of the bis(amine-phenol) nitroimidazole with Tc-99m gave an apparent single complex; this appeared as a broad peak on HPLC analysis. Purification by a solid-phase method gave a complex with 95% radiochemical purity. This complex was not permeable to cultured bovine brain endothelial cells nor did it show preferential uptake in anoxic myocytes.

  DOI：

  10.1021/jm00050a012
• 作为产物：
  描述：

  烯丙基丙二酸二乙酯 在 lithium aluminium tetrahydride 、 氨 作用下， 以 甲醇 、 乙二醇二甲醚 为溶剂， 反应 68.0h， 生成 2-Allyl-1,3-propane diamine
  参考文献：
  名称：

  The Synthesis and in vitro Evaluation of a 99mTechnetium-Nitroimidazole Complex Based on a Bis(amine-phenol) Ligand: Comparison to BMS-181321

  摘要：

  We have developed a (99m)Technetium complex for imaging of hypoxic tissue (BMS-181321). Recently, another nitroimidazole derivative, based upon a bis(amine-phenol) ligand, was described in the patent literature. To compare this compound to BMS-181321, we have synthesized the ligand, prepared its Tc-99m complex, and evaluated its performance in two in vitro assays of bioefficacy: membrane permeability and uptake in normoxic and anoxic cardiocytes. In attempting to reproduce the synthesis of the ligand described in the patent application, we found that one intermediate could not be made by the method described, and alternative routes were investigated. Complexation of the bis(amine-phenol) nitroimidazole with Tc-99m gave an apparent single complex; this appeared as a broad peak on HPLC analysis. Purification by a solid-phase method gave a complex with 95% radiochemical purity. This complex was not permeable to cultured bovine brain endothelial cells nor did it show preferential uptake in anoxic myocytes.

  DOI：

  10.1021/jm00050a012

文献信息

• PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT
  申请人：Wiessler Manfred

  公开号：US20100016545A1

  公开（公告）日：2010-01-21

  The present invention relates to a process for linking two molecules by means of a Diels Alder reaction with inverse electron requirement (DARinv), comprising the following steps: reaction of a (a) triazine or tetrazine with one or more electron-attracting substituents on the ring as a diene component, the electron-attracting substituents being selected from: COOR C(O)NR 2 CX 3 (X=halogen) halogen CN SO 2 —R or SO 3 —R PR 2 wherein R═H, alkyl, aryl, heterocycle, which in turn may be substituted, where appropriate, with alkyl, OH, SH, halogen, aryl, heterocycle, nitro, carboxyamido or amine group. —heterocyclic rings having 1, 2 or 3 N, O or S atoms with a ring size of 5 or 6 ring members, which are substituted with at least one carboxyl, sulfonic acid or phosphone group with (b) an isolated double bond or triple bond in a (hetero)carbocyclic ring or an isolated olefinic double bond or triple bond in a linear or branched hydrocarbon chain which may also contain heteroatoms, where appropriate, as a dienophile component.

  本发明涉及一种利用逆电子需求的Diels-Alder反应（DARinv）将两种分子通过连接的方法，包括以下步骤：将（a）三嗪或四嗪与环上的一个或多个吸电子取代基反应作为二烯组分，所述吸电子取代基被选择自：COOR、C（O）NR2、CX3（X=卤）、卤、CNSO2—R或SO3—RPR2，其中R=H、烷基、芳基、杂环，后者可能被适当地取代，如有必要，可用烷基、OH、SH、卤、芳基、杂环、硝基、羧基氨基或胺基团取代；（b）一种孤立的双键或三键存在于（杂）碳环上，或者一种孤立的烯烃双键或三键存在于线性或支链烃链中，该链也可能含有杂原子，如有必要，作为二烯酰组分。
• Chelating agents for forming complexes with radioactive isotopes, metal
  申请人：Institut fur Diagnostikforschung GmbH

  公开号：US05302370A1

  公开（公告）日：1994-04-12

  The invention relates to compounds having the general formula I ##STR1## where A if required can contain a functional and/or activated group C for coupling to selectively concentrating compounds or can contain a selectively concentrating compound coupled via the group C. B and B' are functional groups for coordinate bonding of groups carrying metal ions. The novel compounds are for forming complexes with radioactive metal ions, more particularly rhenium and technetium isotopes, and are used in medical diagnosis and therapy.

  该发明涉及具有一般式I的化合物 ##STR1## 其中如有需要，A可以包含一个功能性和/或活化的基团C，用于与选择性浓集化合物偶联，或者可以包含通过基团C偶联的选择性浓集化合物。B和B'是用于与携带金属离子的基团进行配位键合的功能基团。这些新型化合物用于与放射性金属离子形成络合物，尤其是铼和锝同位素，并用于医学诊断和治疗。
• Chelatbildner zur Komplexierung von radioaktiven Isotopen, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie
  申请人：INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN

  公开号：EP0417870A2

  公开（公告）日：1991-03-20

  Die Erfindung betrifft Verbindungen der allgemeinen Formel I worin A gegebenenfalls eine funktionelle und / oder aktivierte Gruppe C für die Kopplung an sich selektiv anreichernde Verbindungen oder eine über die Gruppe C gekoppelte sich selektiv anreichernde Verbindung enthalten kann. B und B′ sind funktionelle Gruppen für die koordi­native Bindung von Metallionen tragenden Gruppen. Die neuen Verbindungen dienen zur Komplexierung von radioaktiven Metallionen, insbesondere Rhenium- und Technetium-­Isotopen, und werden in der medizinischen Diagnostik und Therapie eingesetzt.

  本发明涉及通式 I 的化合物 其中 A 可选择性地含有官能团和/或活化基团 C，用于与选择性蓄积化合物或通过基团 C 偶联的选择性蓄积化合物偶联。B 和 B′为官能团，用于与携带金属离子的基团配位结合。新化合物可用于放射性金属离子，特别是铼和锝同位素的络合，并可用于医学诊断和治疗。
• JPS6251645A
  申请人：——

  公开号：JPS6251645A

  公开（公告）日：1987-03-06
• US5302370A
  申请人：——

  公开号：US5302370A

  公开（公告）日：1994-04-12